Neurotech embarks on ground-breaking ASD trials5 May 2021 News & MediaFinfeedNeurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD).